A report into the uptake of patient access schemes in the NHS

Clinical Pharmacist

Volumn 2, Issue 7-8, 2010, Pages 268-270

  Williamson, Steve ^a   Thomson, David ^b  

^a NORTHUMBRIA HEALTHCARE NHS FOUNDATION TRUST   (United Kingdom)

^b Yorkshire Cancer Network   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CETUXIMAB; ERLOTINIB; LENALIDOMIDE; PEMETREXED; RITUXIMAB; SUNITINIB; TOPOTECAN;

ADVANCED CANCER; ARTICLE; BILLING AND CLAIMS; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DRUG COST; FUNDING; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; KIDNEY CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MEDICAL STAFF; MULTIPLE MYELOMA; NATIONAL HEALTH SERVICE; PATIENT RIGHT; QUESTIONNAIRE; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER;

EID: 84861769391     PISSN: 17589061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Department of Health. The Pharmaceutical Price Regulation Scheme. October 2009. www.dh.gov.uk/en/Publicationsandstatistics/Publications/DH-091825 (accessed 19 May 2010).
2. Office of Fair Trading. The Pharmaceutical Price Regulation Scheme. A Market Study. 2007. www.oft.gov.uk/shared-oft/reports/comp-policy/oft885.pdf (accessed 19 May 2010).
3. National Institute for Health and Clinical Excellence. Guide to the single technology appraisal process. Section 5: Patient access and flexible pricing schemes. June 2009. www.nice.org.uk/media/F2B/FC/ Section5PatientAccessFlexiblePricingSchemes.pdf (accessed 19 May 2010).
4. Cook JP, Vernon JA, Manning R. Pharmaceutical risk-sharing agreements. Pharmacoeconomics 2008;27:551-6. (Pubitemid 351871550)
5. British Oncology Pharmacy Association. Cancer Network Pharmacists Forum position statement on "risk sharing" schemes in oncology. March 2008. www.bopawebsite.org (accessed 19 May 2010).
6. Wynd K. Risk sharing schemes - improving patient access to new drugs. Hospital Pharmacist 2008;15:114.
7. Williamson S, Thomson D. Do risk share schemes cause more problems than they solve? British Journal of Clinical Pharmacy 2009;1:54-5.
8. National Institute for Health and Clinical Excellence. Bortezomib monotherapy for relapsed multiple myeloma. October 2007. www.nice.org.uk/ta129 (accessed 21 June 2010).
9. Department of Health. Improving access to medicines for NHS patients: a report for the Secretary of State for Health by Professor Mike Richards. November 2008. www.dh.gov.uk (accessed 21 June 2010).
10. Janssen Cilag. VRS satisfaction research questionnaire. VRS Newsletter; January 2009.